JPWO2020113224A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020113224A5 JPWO2020113224A5 JP2021530875A JP2021530875A JPWO2020113224A5 JP WO2020113224 A5 JPWO2020113224 A5 JP WO2020113224A5 JP 2021530875 A JP2021530875 A JP 2021530875A JP 2021530875 A JP2021530875 A JP 2021530875A JP WO2020113224 A5 JPWO2020113224 A5 JP WO2020113224A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cdr2
- cdr3
- cdr1
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024168470A JP2025011142A (ja) | 2018-11-30 | 2024-09-27 | キメラ抗原受容体ファクトリおよびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773885P | 2018-11-30 | 2018-11-30 | |
| US62/773,885 | 2018-11-30 | ||
| US201962826462P | 2019-03-29 | 2019-03-29 | |
| US62/826,462 | 2019-03-29 | ||
| PCT/US2019/064032 WO2020113224A2 (en) | 2018-11-30 | 2019-12-02 | Chimeric antigen receptor factories and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168470A Division JP2025011142A (ja) | 2018-11-30 | 2024-09-27 | キメラ抗原受容体ファクトリおよびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513668A JP2022513668A (ja) | 2022-02-09 |
| JPWO2020113224A5 true JPWO2020113224A5 (https=) | 2023-04-14 |
| JP2022513668A5 JP2022513668A5 (https=) | 2023-04-14 |
| JP7649239B2 JP7649239B2 (ja) | 2025-03-19 |
Family
ID=70853578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530875A Active JP7649239B2 (ja) | 2018-11-30 | 2019-12-02 | キメラ抗原受容体ファクトリおよびその使用方法 |
| JP2024168470A Pending JP2025011142A (ja) | 2018-11-30 | 2024-09-27 | キメラ抗原受容体ファクトリおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168470A Pending JP2025011142A (ja) | 2018-11-30 | 2024-09-27 | キメラ抗原受容体ファクトリおよびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12577311B2 (https=) |
| EP (1) | EP3887509A4 (https=) |
| JP (2) | JP7649239B2 (https=) |
| KR (1) | KR20210135475A (https=) |
| AU (1) | AU2019387566A1 (https=) |
| CA (1) | CA3119644A1 (https=) |
| WO (1) | WO2020113224A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7269167B2 (ja) * | 2016-10-14 | 2023-05-08 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | モジュラー四価二重特異性抗体プラットフォーム |
| CN109401969B (zh) * | 2018-12-13 | 2024-02-02 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接系统及其使用方法 |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| US20220249640A1 (en) * | 2019-06-14 | 2022-08-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| EP4226972A4 (en) * | 2020-10-12 | 2025-01-01 | Nanjing Iaso Biotechnology Co., Ltd. | CD70-BINDING ANTIBODY AND CHIMERIC ANTIGEN RECEPTORS (CAR) AND THEIR USE |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN114565761B (zh) * | 2022-02-25 | 2023-01-17 | 无锡市第二人民医院 | 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法 |
| CA3250590A1 (en) * | 2022-06-09 | 2023-12-14 | Telix Pharmaceuticals (Innovations) Pty Ltd | POLYTHERAPY |
| KR20250158048A (ko) * | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO2006089141A2 (en) | 2005-02-18 | 2006-08-24 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| WO2007065027A2 (en) | 2005-12-02 | 2007-06-07 | Dana Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
| US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
| DK2686347T3 (en) * | 2011-03-16 | 2018-06-25 | Argenx Bvba | Antibodies against CD70 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
| JP6795505B2 (ja) | 2014-10-06 | 2020-12-02 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法 |
| US20180334490A1 (en) * | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| BR112017013176A2 (en) | 2014-12-19 | 2018-05-15 | Dana-Farber Cancer Institute Inc. | chimeric antigen receptors and methods for using them |
| KR20170093248A (ko) | 2014-12-19 | 2017-08-14 | 다나-파버 캔서 인스티튜트 인크. | 탄산무수화효소 ix 특이적 키메라 항원 수용체 및 이의 사용 방법 |
| US10738116B2 (en) * | 2015-03-19 | 2020-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dual specific anti-CD22-anti-CD19 chimeric antigen receptors |
| WO2016174652A1 (en) * | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| EP3288977B1 (en) | 2015-05-01 | 2021-11-17 | Dana-Farber Cancer Institute, Inc. | Methods of mediating cytokine expression with anti ccr4 antibodies |
| JP7115982B2 (ja) * | 2015-10-30 | 2022-08-09 | アレタ・バイオセラピューティクス・インコーポレイテッド | 癌の治療のための組成物及び方法 |
| PT3583129T (pt) | 2017-02-14 | 2021-12-14 | Kite Pharma Inc | Moléculas de ligação a cd70 e seus métodos de uso |
| MA47613A (fr) | 2017-02-22 | 2020-01-01 | Aleta Biotherapeutics Inc | Compositions et procédés de traitement du cancer |
| AU2019235900B2 (en) | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
-
2019
- 2019-12-02 WO PCT/US2019/064032 patent/WO2020113224A2/en not_active Ceased
- 2019-12-02 CA CA3119644A patent/CA3119644A1/en active Pending
- 2019-12-02 KR KR1020217019851A patent/KR20210135475A/ko not_active Ceased
- 2019-12-02 EP EP19889550.0A patent/EP3887509A4/en active Pending
- 2019-12-02 JP JP2021530875A patent/JP7649239B2/ja active Active
- 2019-12-02 AU AU2019387566A patent/AU2019387566A1/en active Pending
- 2019-12-02 US US17/298,271 patent/US12577311B2/en active Active
-
2024
- 2024-09-27 JP JP2024168470A patent/JP2025011142A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Wu et al. | Recent advances and challenges of bispecific antibodies in solid tumors | |
| US20220202904A1 (en) | Combined pharmaceutical composition | |
| Roselli et al. | Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes | |
| JP2022066290A5 (https=) | ||
| Frigault et al. | Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma | |
| AU2020276242B2 (en) | Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer | |
| Fucà et al. | Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy | |
| JPWO2020113224A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2021531754A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| JP2020522495A5 (https=) | ||
| JP2022159548A5 (https=) | ||
| JP2020527144A5 (https=) | ||
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JPWO2020014285A5 (https=) | ||
| JP2017537892A5 (https=) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2021518104A5 (https=) | ||
| JP2024054286A5 (https=) | ||
| CN114502595B (zh) | 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途 | |
| JP2022501361A5 (https=) | ||
| JP2020533962A5 (https=) |